Cost-effectiveness profile, organizational implications and patient preferences on the use of exogenous TSH therapy (Thyrogen®) vs. THW in thyroid residue ablation in Italy. (2016). Farmeconomia. Health Economics and Therapeutic Pathways, 17(3). https://doi.org/10.7175/fe.v17i3.1264